FDA Employee Misconduct Charges To Be Investigated By OIG Instead Of Itself

A "stronger appearance of impartiality, integrity" will result from an HHS Office of Inspector General decision to take back investigative authority over allegations of employee misconduct at FDA, a GOP aide to the House Energy & Commerce Committee told "The Pink Sheet.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet